Blog
Aetion, Dr. Scott Gottlieb, biopharma leaders’ discussions at JPM 2020: It’s time to “knock on an open door” to further RWE standards and acceptance
This January, in the whirlwind week of the 36th Annual J.P. Morgan Healthcare Conference ...
Blog
How to amplify RWE clarity and reproducibility with data visualizations: Q&A with Dr. Shirley Wang of the REPEAT initiative
While analyses of non-randomized health care databases—insurance claims, electronic ...
Blog
Artificial Intelligence in Health Care - GAO Report
Benefits and Challenges of Machine Learning in Drug Development The adoption of ...
Blog
Why diverse data teams lead to bigger wins, and other perspectives from retail tech: A Q&A with Stitch Fix CTO, Cathy Polinsky
Cathy Polinsky’s deep love of programming, problem-solving, and perfecting client ...
Blog
How emerging technologies will ensure increasing availability of RWD
The potential of real-world data (RWD) to transform clinical trials is drawing attention ...
Blog
Contextual considerations in RWE generation and use
There’s a lot of buzz around the potential impact of real-world evidence (RWE) in health ...
Blog
The shift from health technology assessment to management: What is RWE’s role?
As innovation in health care advances—and the associated costs escalate—payers are ...
Blog
RWE use by HTAs: How has it evolved, and where is it headed next? Q&A with Dr. Jens Grueger
Health technology assessment (HTA) agencies are increasingly turning to real-world ...
Blog
RWE and the value equation: U.S. health care purchaser perspectives on payment model evolution and the role of RWE
Much discussion surrounds rising drug prices—and the numerous parties affected. ...
Blog
Let’s talk about value: How biopharma can maximize utility of RWE in value discussions
With the drug pricing pressures mounting on a global scale, there is a clear and imminent ...
Blog
Ask our experts: Working with real world data sets: What types of questions can your data answer?
The promise of real-world evidence (RWE) comes with a steep learning curve. As regulators ...
Blog
Managing the Risks from AI Algorithms
In the webinar organized by Replica Analytics in November 2019 entitled "Managing the ...
Blog
Advancing cancer care with real-world data: Next steps for collaborators
In oncology, over 90 percent of patient treatment experiences occur outside of clinical ...
Blog
Evidence at the Apex: Five learnings from the first annual Aetion Summit
Last month, the inaugural Aetion Summit in New York City brought together some of the ...
Blog
Learnings from three FDA decisions on ECA submissions in oncology
The publication of the Framework for FDA’s Real-World Evidence Program nearly a year ago ...
Blog
Spotlight on trust and transparency at ISPOR Europe 2019
The digital age has transformed the amount and quality of data available and given rise ...
Blog
Bold moves in RWE — from FDA, industry, and tech at HLTH 2019
Two weeks ago, researchers at NYU published new findings on how objects move against a ...
Blog
RWE advances amidst “data tsunami”: Takeaways from FOCR 8th Annual Blueprint for Breakthrough Forum
Breakthroughs in data extraction and analysis coupled with federal infrastructure ...
Blog
FDA’s Technology Modernization Action Plan: Three ways to prepare for the coming RWE infrastructure
The U.S. Food and Drug Administration (FDA) recognizes that common standards and a shared ...
Blog
The case for real-world evidence in health technology assessment
New drugs are launched based on data from randomized controlled trials (RCTs), the gold ...
Blog
On FHIR: How “Fast Healthcare Interoperability Resources” will improve real-world data quality
In 2009, health care data entered the digital age with the HITECH Act and the ...
Blog
Everyone in the pool: How diverse stakeholders speed RWE adoption
A recent issue of Clinical Pharmacology & Therapeutics focused entirely on real-world ...
Blog
Takeaways from the 35th ICPE
At the end of August, pharmacoepidemiology enthusiasts from across the globe gathered in ...
Blog
What can electronic health records tell us—and how? Q&A with Andrew Bate, Ph.D.
As pharma manufacturers and regulatory agencies increase the role of real-world data ...